<div id="readability-page-1"><p>CIBC Asset Management Inc lifted its stake in  IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 18.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor  owned 283,243 shares of the medical research company's stock after buying an additional 44,732 shares during the period. CIBC Asset Management Inc owned about 0.17% of IQVIA worth $44,636,000 at the end of the most recent reporting period.</p><p>A number of other large investors have also recently bought and sold shares of IQV. Verdence Capital Advisors LLC acquired a new position in  IQVIA during the 2nd quarter worth $3,612,000.  Act Two Investors LLC bought a new stake in shares of  IQVIA during the second quarter worth $26,528,000.  Amundi lifted its stake in shares of  IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company's stock valued at $210,722,000 after acquiring an additional 405,250 shares during the period.  Patton Fund Management Inc. bought a new position in  IQVIA in the second quarter valued at about $231,000.  Finally, Shell Asset Management Co. raised its holdings in  IQVIA by 78.7% during the 2nd quarter. Shell Asset Management Co. now owns 9,256 shares of the medical research company's stock worth $1,459,000 after purchasing an additional 4,077 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors. </p><h2>IQVIA Price Performance</h2><p>IQV opened at $225.64 on Friday. The company has a fifty day simple moving average of $216.71 and a 200 day simple moving average of $188.73. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock has a market cap of $38.43 billion, a P/E ratio of 30.95, a P/E/G ratio of 2.50 and a beta of 1.37. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $234.29. </p><p>IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analysts' expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company's revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS.  On average, research analysts expect that  IQVIA Holdings Inc. will post 10.84 EPS for the current year. </p><h2>Insider Transactions at IQVIA</h2><p>In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own  1.60% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several brokerages have recently issued reports on IQV. Stifel Nicolaus raised their target price on shares of IQVIA from $234.00 to $254.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, October 29th. Redburn Partners  set a $214.00 target price on shares of IQVIA in a report on Wednesday, September 3rd. Hsbc Global Res upgraded IQVIA from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, October 9th. Citigroup lifted their price objective on IQVIA from $200.00 to $230.00 and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday, October 29th. Finally, BMO Capital Markets began coverage on IQVIA in a research note on Thursday, November 13th. They issued an &#34;outperform&#34; rating and a $260.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $241.44.</p><p><b>Read Our Latest Analysis on IQV</b></p><h2>IQVIA Profile</h2> (Free Report)<p>IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology &amp; Analytics Solutions, Research &amp; Development Solutions, and Contract Sales &amp; Medical Solutions.</p><h2>Read More</h2><ul><li>Five stocks we like better than IQVIA</li><li>3 Stocks to Consider Buying in October</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>Breakout Stocks: What They Are and How to Identify Them</li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li><li>What Makes a Stock a Good Dividend Stock?</li><li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li></ul><p><strong>Want to see what other hedge funds are holding IQV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in IQVIA Right Now?</h2><p>Before you consider IQVIA, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.</p><p>While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>CIBC Asset Management Inc increased its stake in IQVIA Holdings Inc by 18.8% in Q2, acquiring 44,732 shares. Analysts have issued various ratings, with a consensus price target of $241.44 and a "Moderate Buy" average rating. IQVIA reported Q3 earnings of $3.00 per share, beating estimates, and set FY 2025 guidance at 11.850-11.950 EPS.</p>

CIBC Asset Management Inc Acquires 44,732 Shares of IQVIA Holdings Inc. $IQV